China adds 84 key foreign-funded projects, total investment $19.46B

This signals a deliberate policy push to anchor high-profile multinationals in China, particularly in advanced manufacturing and R&D, as part of a broader strategy to stabilize foreign investment amid geopolitical headwinds. The inclusion of landmark projects like AstraZeneca's global R&D center underscores a focus on knowledge-intensive sectors, which could reshape supply chain dynamics. The immediate significance lies in whether this translates into sustained capital inflows beyond the selected projects, or remains a targeted gesture. Watch if similar project lists expand to other regions or industries, and how approval timelines and operational follow-through evolve.